Tipping Comp - what will RAP’s Revenue be sales in Sept. Qtr, page-52

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 52 Last

Share
Profile

Follow
Tech goose

2,710 Posts.

506

28/09/20

14:35

Post #: 47679833
Share

Originally posted by rajboon ↑

I say In my opinion, TK must leave and the company should get a better CEO who can sell the product.
We are in the middle of the worst respiratory-related pandemic of the century.
ResApp has a respiratory disease diagnostic product which can be utilized during this pandemic
Still, our CEO cant sell
TK list of negative achievements or failures:
1. Failed 1st US trial, maybe because of his careless or stubborn attitude?
2. Doctors without border exiting the project
3. Less than optimal results in 2nd US trial
4. Sanofi exiting
5. FDA rejection
6. Millions of dollars in capital raise
7. He got millions of shares for 1c and 2c and 5c?
8. His annual salary >280k

I am sure he has some success as well like successful Australian clinical trial, TGA, CE approval, COVIU, Phenix deals, etc. but if we look back and assess his failures will definitely outweigh his success.
My problems with him are:
His stubbornness
not learning from his mistakes
not be sorry and own responsibilities
his lies about capital raise and company position

This may be my first post on resapp, but I have been following this company since the start & know its history. I know mostly all posters (downramper, upramper, genuine...) on this forum and I respect their knowledge.

Expand

I just forwarded your post to TK to light a fire under his butt

Last edited by Tech goose: 28/09/20

RAP Price at posting: 10.5¢ Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

HAS

Hastings progressing Yangibana to production with lower costs

ZNC

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

The iron ore comeback: Can it last?

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia